Skip to Content

Tilray Brands Inc TLRY

Morningstar Rating
$1.81 −0.03 (1.63%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Cannabis Shares Rally (Again) on Next Incremental Step to Federal Rescheduling

Shares of Canadian-licensed producers and US multistate operators rallied massively on news that the US Drug Enforcement Administration will proceed with rescheduling cannabis to Schedule III from Schedule I. Schedule I indicates it is considered to have a high potential for abuse and no medical value. In comparison, Schedule III drugs are considered less dangerous, with a lower potential for abuse and having some medical value. We view the April 30 news as the next step in a long process by the Biden administration to relax the current federal prohibition. We view the market reaction as a reflection of how much pressure these stocks have faced rather than any new development.

Price vs Fair Value

TLRY is trading at a 896% premium.
Price
$1.85
Fair Value
$5.00
Uncertainty
Very High
1-Star Price
$9.60
5-Star Price
$7.00
Economic Moat
Lwl
Capital Allocation
Ftwnfrmhp

Bulls Say, Bears Say

Bulls

Tilray's better financial health and profitability lead compared with Canadian peers positions it to lead its home market.

Bears

The existence of the illicit market limits the potential price increases Tilray can push through to consumers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLRY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.84
Day Range
$1.801.86
52-Week Range
$1.513.40
Bid/Ask
$1.81 / $1.82
Market Cap
$1.49 Bil
Volume/Avg
11.7 Mil / 35.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.78
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.08%

Company Profile

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
1,600

Competitors

Valuation

Metric
TLRY
CRON
ACB
Price/Earnings (Normalized)
1,623.62
Price/Book Value
0.430.940.81
Price/Sales
1.7810.821.18
Price/Cash Flow
Price/Earnings
TLRY
CRON
ACB

Financial Strength

Metric
TLRY
CRON
ACB
Quick Ratio
0.9621.681.79
Current Ratio
1.9222.543.79
Interest Coverage
−4.39
Quick Ratio
TLRY
CRON
ACB

Profitability

Metric
TLRY
CRON
ACB
Return on Assets (Normalized)
−1.42%−0.53%
Return on Equity (Normalized)
−1.82%−0.55%
Return on Invested Capital (Normalized)
−0.92%−4.90%
Return on Assets
TLRY
CRON
ACB
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRSxglktjyjhRjpgw$78.9 Bil
ZTS
Zoetis Inc Class ANdgkkhzmtRfzh$77.6 Bil
HLN
Haleon PLC ADRWzxrsrzvPkqv$37.6 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRZlwfxkcTfvf$18.8 Bil
VTRS
Viatris IncZwtfzhlvrVtjy$12.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRDqrnrllDshmy$11.8 Bil
CTLT
Catalent IncDdhgxsyntFgmxyj$9.9 Bil
PRGO
Perrigo Co PLCGdptstmWlmj$3.8 Bil
CURLF
Curaleaf Holdings IncRtsvbzbCqnd$3.4 Bil
PBH
Prestige Consumer Healthcare IncYkgpckzRftmy$3.2 Bil

Sponsor Center